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Thirty percent of medullary thyroid carcinomas (MTC) are related to dominant
germline pathogenic variants in the RET proto-oncogene. According to their
aggressiveness, these pathogenic variants are classified in three risk levels:
'moderate', 'high' and 'highest'. The present study compares the metabolomics
profiles of five pathogenic variants, whether already classified or not. We have
generated six stable murine fibroblast cell lines (NIH3T3) expressing the wild-type
allele or variants of the human RET gene, with different levels of pathogenicity,
including the M918V variant that has yet to be accurately classified. We carried out a
targeted metabolomics study of the cell extracts with a QTRAP mass spectrometer,
using the Biocrates Absolute IDQ p180 kit, which allows the quantification of 188
endogenous molecules. The data were then subjected to multivariate statistical
analysis. One hundred and seventy three metabolites were accurately measured. The
metabolic profiles of the cells expressing the RET variants were found to be
correlated with their oncogenic risk. In addition, the statistical model we constructed
for predicting the oncogenic risk attributed a moderate risk to the M918V variant.
Our results indicate that metabolomics may be useful for characterizing the
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